首页> 外文期刊>European neurology >Bone disease induced by phenytoin therapy: clinical and experimental study.
【24h】

Bone disease induced by phenytoin therapy: clinical and experimental study.

机译:苯妥英钠治疗引起的骨病:临床和实验研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies have made references to prolonged treatment with phenytoin as a possible risk factor in the development of osteoporosis and/or osteomalacia. We studied a group of 30 epileptic patients who were under long-term treatment with phenytoin (DPH) in an ambulatory regimen. We found the prevalence of osteoporosis to be 3.3% and of osteopenia to be 56.6%, affecting predominantly the femur, without any significant decrease in bone mineral density of the lumbar spine. These patients were showing signs of bone turnover uncoupling with increases in bone resorption markers. At this time, they also exhibited slight alterations in their phosphocalcium metabolism with trends to hypocalcemia and secondary hyperparathyroidism that was found not to be caused by a vitamin D deficiency as the serum levels of 25(OH)D and 1,25(OH)(2)D were normal. With the aims of corroborating these results and to investigate the physiopathological effects on the bone induced by anticonvulsant drugs we developed a further experimental study in which we administered DPH over a 6-week period with a dose of 5 g/kg/day to male Wistar rats that were in the growth phase. This treatment produced a decrease in overall BMD and bone mineral content in the femur. We did not find osteomalacia in the vertebral biopsy, but the administration of DPH to these animals decreased trabecular volume as well as lessened the thickness of osteoid edges together with an uncoupling in bone turnover. There was also a marked decrease in bone formation and a tendency towards increased bone resorption. We have also found a decrease in resistance to fracture by torsion in the biomechanical assay, which translates into an increase in bone fragility. In these male Wistar rats, the administration of DPH produced a tendency towards increasing the markers of resorption and, though changes in serum levels of calcium and phosphorus were not observed, to provoke an increase in the parathyroid hormone levels; with normal levels of 1,25(OH)(2)D which has produced the same inclination in rats as in humans.
机译:以前的研究已经提到长期使用苯妥英钠作为骨质疏松症和/或骨软化症发展的可能危险因素。我们研究了一组30名癫痫患者,他们在非卧床方案中长期接受苯妥英钠(DPH)治疗。我们发现骨质疏松症的患病率为3.3%,骨质疏松症的患病率为56.6%,主要影响股骨,而腰椎的骨矿物质密度没有显着降低。这些患者显示出骨转换的迹象与骨吸收标记物增加无关。此时,他们的钙磷代谢也有轻微改变,并有低血钙和继发性甲状旁腺功能亢进的趋势,这被发现不是由维生素D缺乏引起的,因为血清中的25(OH)D和1,25(OH)( 2)D正常。为了证实这些结果并研究抗惊厥药物对骨骼的生理病理学影响,我们开展了进一步的实验研究,其中我们在6周内以5 g / kg /天的剂量向雄性Wistar施用了DPH。处于生长期的大鼠。这种治疗降低了股骨的总体骨密度和骨矿物质含量。我们在椎骨活检中未发现骨软化症,但向这些动物施用DPH可以减少小梁体积,并减少类骨质边缘的厚度以及骨转换的解耦。骨形成也明显减少,并且骨吸收增加的趋势。我们还发现在生物力学测定中抗扭转断裂的能力降低,这转化为骨脆性的增加。在这些雄性Wistar大鼠中,DPH的给药有增加再吸收标志物的趋势,尽管未观察到血清钙和磷水平的变化,却引起甲状旁腺激素水平的升高。正常水平的1,25(OH)(2)D在大鼠中产生的倾角与人类相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号